Get Started

LCTX

AMEX Lineage Cell Therapeutics, Inc.
Oct 24, 2026 · 5:37 AM ET EOD Market Closed

$1.00 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.00, $0.01 below the day’s high of $1.02

YTD change
-40.12%
vs 20-day SMA
+4.24%
vs 200-day SMA
-25.81%

Price ranges

Previous day
$0.94 $1.02
open $0.97 close $1.00
+$0.03 (+3.55%)
Today
$0.94 $1.02
$1.00
Past week
$0.94 $1.01
from $0.99 now $1.00
+$0.01 (+0.98%)
Past month
$0.88 $1.05
from $0.95 now $1.00
+$0.05 (+5.51%)
This year
$0.88 $1.99
from $1.67 now $1.00
-$0.67 (-40.12%)

Price & Performance

-0.55 (-35.48%) / 6M

$0.8517$1.11$1.36$1.61Apr 24Jul 27Oct 23

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral
  • The stock is 68.1% away from all-time highs of $3.13
  • LCTX is down 40% since the beginning of the year
  • LCTX is down 39% over the past 12 months
  • LCTX is up 6% over the past 1 month
  • 15% of all LCTX investors are betting against LCTX
  • Number of investors short LCTX has gone down 2% versus last month

LCTX reads neutral: price sits above one of the two key moving averages, short interest is falling month over month, the 12-month move is -41.2%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.03
Earnings momentum -5.0% Quarterly EPS growth
Quarterly change -5.0%

Valuation

P/E ratio N/A
Enterprise value $207.9M
Beta 1.55

Balance sheet & scale

IncomeN/A
Revenue$13.1M
Cash$50.8M
Debt$2.3K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeAMEX
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $252.9M

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The company's pipeline consists of seven allogeneic cell transplant therapy programs spanning clinical to research stages, targeting a range of conditions including dry-AMD, spinal cord injuries, auditory neuropathy, Type 1 Diabetes, and vision loss, with several programs supported by strategic partnerships with Roche, Genentech, William Demant Invest, and Factor Biosciences. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $439.26 -1.79%
MRNA Moderna, Inc. $200.10 -1.25%
RVMD Revolution Medicines, Inc. $186.99 -0.37%
ROIV Roivant Sciences Ltd. $36.49 -2.56%
BNTX BioNTech SE Sponsored ADR $88.12 -1.73%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.